Table 2.

Association of impaired fasting glucose, diabetes and their treatment with mortality in 1637 patients with peripheral artery disease across 4 regression models

	Model 1		Model 2		Model 3		Model 4
Patient group	HR	P value	HR	P value	HR	P value	HR	P value
	(95% CI)		(95% CI)		(95% CI)		(95% CI)
No diabetes	1.00		1.00		1.00		1.00
	(reference)		(reference)		(reference)		(reference)
Impaired fasting glucose	1.02	0.901	0.99	0.967	1.01	0.949	1.01	0.925
	(0.77-1.35)		(0.75-1.32)		(0.76-1.35)		(0.76-1.35)
Non-medicated diabetes	1.73	0.003	1.63	0.009	1.64	0.008	1.62	0.011
	(1.21-2.48)		(1.13-2.35)		(1.14-2.37)		(1.12-2.34)
Diabetes prescribed oral hypoglycaemics only	1.11	0.522	1.03	0.870	1.01	0.935	1.03	0.874
	(0.80-1.54)		(0.74-1.43)		(0.72-1.43)		(0.73-1.45)
Diabetes prescribed insulin	2.94	<0.001	2.28	0.001	1.98	0.006	1.97	0.007
	(1.86-4.66)		(1.42-3.66)		(1.21-3.23)		(1.20-3.23)

Models include the following covariates.

Model 1: Age and sex.

Model 2: Age, sex, hypertension, ever smoking, coronary heart disease and presenting complaint.

Model 3: Age, sex, hypertension, ever smoking, coronary heart disease, presenting complaint, statin prescription, aspirin prescription, other anti-platelet prescription, beta blocker prescription, calcium channel blocker prescription, angiotensin converting enzyme inhibitor prescription, angiotensin receptor blocker prescription and frusemide prescription.

Model 4: Age, sex, hypertension, ever smoking, coronary heart disease, presenting complaint, statin prescription, aspirin prescription, other anti-platelet prescription, beta blocker prescription, calcium channel blocker prescription, angiotensin converting enzyme inhibitor prescription, angiotensin receptor blocker prescription, frusemide prescription and eGFR. Please note, 15 patients with missing serum creatinine values were excluded from this analysis.